Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
American OCAT patients needs that are focused upon to be resolved and "now" have a way. Who would deni them?
American IP made in the states, should stay here unless licensed out to other countries.
As OCAT's victories over Japan/Astellas sinks in, glad to be solid with this opportunity and purpose in "hand".
Zaroa-God's Right Hand is thought to be a symbol of strength and power. ... The noun for arm translates the Hebrew "zaroa" and means shoulder or power or strength.
Why are the mature OCAT shareholders buying/holding with a bigger purpose and not tendering?
OCAT has the ability to help 2000 Americans dying every day from Sepsis in our hospitals. This is another reason to buy, hold and not tender OCAT shares. And untendering shares is a good thing for the above reason. The billionaire Mario Gabelli has bought over 5% OCAT shares along with Blackrock and Vanguard.
With lots of advancements in OCAT science supporting improvement in macular degeneration patients proven in the Lancet Peer Reviewed Scientific Journal, the mindboggleing part is the lack of respect and the amount of sarcasm thrown in by a few OCAT posters trying to bolster their appearance like one of those hooded lizards that has its skin expand to make themselves appear bigger than they really are to approaching adversary. As a contrary statement, I could see reason for their technique if they were fighting products that were destructive, and shown to cause problems. However, OCAT has a long term safety and improvement record and this product to help people is truly in need.
Therefor imo is the reason to buy, hold and not tender OCAT shares is obvious in it's purpose.
For the record, with respect to efforts in favor of OCAT shareholders i have not and will not tender my shares. Some are untendering their shares. I see no reason to tender and bought more OCAT shares into my Roth account. I'm for quantum leap.
BigWorm129 thank you for your perspective i'm in agreement.
My respect to all that have supported the development of OCAT science to help the afflicted. We have won back to back tender battles and keep steady on course and action that which supports goals towards vision of our desired outcome. Thankful for strategies known and unknown to non supporters. Ruthlessness goes both ways.
One of the fun things about OCAT shareprice-moving-up in the green is that you can spot those trying to scare you into selling your shares and you can guess at their agenda and what they are afraid of.
Why is the OCAT science which is without-any-doubt in the "Billion" dollar value range?
Why is the clear OCAT goal of turning down the third tender well fixated in the minds of those in control of their own OCAT shares.
Thanks Lasers, lets put it another way. Back-to-Back-to-Back homeruns for OCAT shareholders. The first homerun is what the Lanza/Team has done for American Macular Degeneraton Patients and meant for thousands and millions more.
Why do people care about American Macular-Degeneration Patients? Why is the true-message that OCAT shareholders have accumulated two back to back victories under their belt and show they have abilities for three to keep OCAT medical advancements here in America to help our macular degeneration patients?
Why do approx. 40,000 OCAT/shareholders including billionaire-Mario Gabelli have abilities to stand together and keep Dr. Lanza's/team medical advancements here in America? Why is a strong JV acceptable?
Why are OCAT shareholders strong together?
Total number of shareholders
OCAT shareholders stand against buyout twice.
"Reader's Digest ASIA-Ocata-Medical Breakthroughs 2016
Medical Breakthroughs 2016 | Health | Reader's Digest Asia
Medical Breakthroughs 2016 (Guess who made this very short list???!!!)
Some of the most amazing latest advances in medical research that will improve your health – starting from right now.
First New Antibiotic in 30 Years
In January 2015, scientists at the University of Bonn in Germany, in collaboration with Northeastern University in Boston, announced the discovery of an antibiotic that has the potential to work against a broad range of fatal infections such as pneumonia, tuberculosis, and blood and soft tissue infections.
Studies show that the drug, called teixobactin, is highly unlikely to lead to drug resistance, one of the biggest stumbling blocks in developing new antibiotics as well as being a major health problem today. Teixobactin was especially effective against tuberculosis, a disease that is on the comeback in many countries, especially in Eastern Europe. The new antibiotic is expected to receive approval in Europe and the US within five years.
Don’t Cut the Cord – Just Yet
Of the many complications premature babies can experience, the most common is bleeding in the brain, the leading cause of premature infant death. Now, researchers from the Dallas-based Baylor Research Institute, led by principal investigator Dr Arpitha Chiruvolu, have found that merely waiting 45 more seconds before clamping the umbilical cord can significantly reduce this risk.
“We were impressed especially by the reduction in [bleeding in the brain] by almost 50 per cent,” she said. “There were no adverse effects and significantly fewer babies who got delayed cord clamping were intubated for apnoea or respiratory diseases in the delivery room.”
Quick Test for Deadly Fevers
Imagine being able to quickly identify deadly, highly contagious haemorrhagic fevers such as Ebola, dengue and yellow fever in hospitals in remote or underdeveloped areas, so that precious time is not lost in starting treatment or implementing quarantine.
Such a test, in the form of a set of colour-changing strips, has been developed by researchers at The Massachusetts Institute of Technology, working with the US Food and Drug Administration. The strips work similarly to pregnancy strip tests and can alert healthcare workers to the possible presence of a specific deadly viral infection, turning orange for yellow fever, red for Ebola and green for dengue.
The new strips will not replace more accurate testing procedures that are conducted in laboratories. “This is a complementary technique for places with no running water or electricity,” says Dr Kimberly Hamad-Schifferli, one of the team leaders. “We’re trying to move this into the field and put it in the hands of the people who need it.”
Womb Transplant
There is new hope for women who because of birth defects or cancer treatments are left without a functioning womb. A Swedish woman gave birth to a healthy baby boy following a successful uterus transplant in September 2014. Malin Stenberg, 37, was born without a uterus; the womb was donated by a 61-year-old family friend. Dr Mats Brännström at the University of Gothenburg, Sweden, led an international team of medics and support staff that performed the transplant.
As this edition went to print, four women in Sweden had given birth following successful transplants.
A Portable Breathing Lung
In 2013 transplant specialists at University Hospital in Leuven, Belgium, succeeded in preserving donor lungs outside the body for 11 hours, the longest time in medical history. This is good news for those who suffer from chronic lung disease and failure and are waiting for transplants.
This is thanks to OCS LUNG, a portable machine that supplies the donor lungs with a continual, fresh supply of oxygen. Developed by TransMedics, a US company, the machine will revolutionise lung transplants by enabling surgeons to preserve and monitor donor lungs for longer between sites. It is now commercially available in Europe and Australia.
New Help for Those Losing Their Sight
Last year Ocata Therapeutics announced the start of its second phase of studies into a human embryonic stem cell therapy. The US-based company’s research could help restore disintegrating eyesight due to age-related macular degeneration.
In the most common form of the disease, a thin layer of tissue that delivers nutrients and oxygen to the eye’s rods and cones begins to deteriorate. Without these nutrients, eyesight begins to be compromised. Ocata coaxes stem cells to become healthy tissue - the retinal pigment epithelium cells – that can then be injected into the eyes. In the company’s first two clinical trials, ten of 18 people experienced some improvement in their vision and the therapy seemed to halt its loss in another seven. It is hoped that the treatment may one day be as common as cataract surgery.
Turning the Tide on a Child Killer
In July 2015, the European Medicines Agency announced its recommendation to approve what could be the world’s first licensed vaccine against malaria in infants and children.
According to the World Health Organization, in 2013 there were an estimated 627,000 deaths from malaria – almost 90% were in sub-Saharan Africa and 77% were children under five. The latest clinical trial for the new vaccine, Mosquirix, showed that four doses of the vaccine reduced malaria cases by almost 40%.
Much of the credit for the vaccine is being attributed to husband-and-wife team Professors Ruth and Victor Nussenzweig, at the Department of Microbiology at NYU Langone, US, whose research of the past 50 years or so against malaria has brought them international recognition. Now in their 80s, the Nussenzweigs are working to improve the vaccine’s efficacy.
Filtering Water with a Book
As many as 358 million people in sub-Saharan Africa do not have reliable access to safe drinking water. Now researchers have come up with a book on water safety, the pages of which can be used to filter water. In trials in South Africa, Haiti, Kenya and Bangladesh, the paper successfully removed more than 99% of bacteria. One page can purify up to 100 litres of water. Each thick, sturdy sheet of paper is embedded with silver nanoparticles, which are lethal for microbes.
Dr Theresa Dankovich, a researcher at Carnegie Mellon University in the US who developed and tested the technology over several years working with colleagues at the University of Virginia and Canada’s McGill University is hoping to start trials in which local residents use the filters themselves. Each page carries instructions in the local language.
“We need to get it into people’s hands to see what the effects are going to be,” says Dr Dankovich.
Vaccine Improves Survival in Lung Cancer Patients
All cells, including cancer cells, need various naturally occurring “growth factors” in order to proliferate. Now Cuban scientists have developed what appears in early clinical trials to be a safe and remarkably effective vaccine, CIMAvax EGF, that inhibits the body’s production of epidermal growth factor (EGF), used by certain cancer cells.
According to Dr Kelvin Lee of Roswell Park Cancer Institute, New York, adult patients with stage IIIB/IV non-small-cell lung cancer (NSCLC), who received CIMAvax survived significantly longer than those who didn’t. Their cancers didn’t disappear but grew much more slowly. Dr Lee, who, with his colleagues, is now seeking permission from the US Food and Drug Administration to offer CIMAvax in a trial says, “There are a lot of other cancers that utilise EGF as a growth factor. Colon, breast, head and neck, pancreatic and prostate cancers all do.” Which means it is possible CIMAvax can slow or stop these, too."
This post came from ICELL STEMDYNASTY
Justarookie, thankyou for keeping your word here at OCAT.
Why is todays OCAT current desired reality different than $OCAT's future desired reality. Why are the patients with macular degeneration worthy of improvments? Why is it possible for 20/40 or better to happen, over and over again?
For those that think they are smarter than Mario Gabelli, Vanguard and Blackrock each one has been loading up with OCAT shares, good luck with your contrarian opinion.
The OCAT's true value is much higher. Astelles would not buy at $8.50 if there was not an upside to the offer price of $8.50 for them. Astellas is in it to win it but anything is possible to happen with OCAT's billionare shareholders top institutions as Lasers has said. If another company shows up...so be it.
There must be a reason why some people change?
Was moving up to the NASDAQ a rumor? Was success in a Scientific Journal a rumor? Was 20/40 from 20/400 a rumor?
What is the difference between possibility and rumor?
How do you mean that? Do you have rights that others do not have?
That is right and why would Gabelli not be buying when one thinks about it to add to his 5% already accumulated. Billion type guys accumulate.
When you look at the whole ensemble, OCAT's unrealized value goes up with science advancements.
OCAT Dr. Robert Lanza involved with this. "showing promise for systemic lupus"
http://www.nature.com/articles/srep17685
Thanks Reetala, was out knocked for several days with sickness and the worst is now behind me. Go OCAT
Mario Gabelli buying into OCAT along with "huge-institutions" is a fact. Mario Gabelli is a multi-billionaire, he is able to start "mo-mo" with his influence. Mario Gabelli refused to hide under his desk as a schoolboy in air raid drills.
Reiterate the positive truth about OCAT trials that GEHC Steven Minger likes.
"Positive Stem Cell Clinical OCATA Trial Results"
"Although the primary goal of this small early-stage clinical trial was to assess the safety of the transplanted stem cells, the treatment also had unexpected positive benefits: Ten out of 18 study participants reported improvements in vision, with some subjects reporting dramatic improvements. In addition, the treatment appears to have halted the progression of the disease in 17 of the 18 subjects."
Results come from five of the most respected eye hospitals in the world and PEER REVIEWED RESULTS were recorded in the Lancet Scientific Journal of OCATA "positive" results.
GEHC Steven Minger likes OCATA/ACT. 1:14 minutemark ACT is now OCATA.
This is true, not saying it will lead to anything or not lead to anything.
Dr. Stephen Minger is Global Head of Research and Development for the Cell Technologies business of GE Healthcare Life Sciences and, in this role, Dr. Minger travels the world to stay current and connected with what’s happening in the regenerative medicine industry. He shares his thoughts about the industry in this video.
Dr. Minger leads the development of GE Healthcare Life Sciences’ cell-based technologies for use in drug discovery and pharmaceutical research. He also directs the development of GE Healthcare Life Sciences’ enabling technologies for the rapidly emerging field of regenerative medicine and cell therapy.
https://vimeo.com/78571115
"Positive Stem Cell Clinical OCATA Trial Results"
"Although the primary goal of this small early-stage clinical trial was to assess the safety of the transplanted stem cells, the treatment also had unexpected positive benefits: Ten out of 18 study participants reported improvements in vision, with some subjects reporting dramatic improvements. In addition, the treatment appears to have halted the progression of the disease in 17 of the 18 subjects."
How come suitors exist without shareholders knowledge? Astellas connections existed before shareholders knowledge. How many others have shown interest? Many companies in past events have shown appreciation for OCAT's Lanza Teams science advancements. Now that OCAT has the data there are many ways to "try to trick" people out of their shares however, it's not working. Shareholders rule turning down tender and have the most energy towards a worthy goal with a billionaire buying OCAT along with institutions. Persistence pays.
I would personally like to thank naysayers as well. They have helped solidify my commitment towards the goal of helping the afflicted for a win/win advancement.
Helping the afflicted has worthy purpose. Thankfully OCAT's Lanza Team has leaped and bounded into advancements. No wonder institutions and billionares are into this purpose for a win/win endeavor.
My appreciation today goes out to OCAT shareholders that are fully engaged, living in the now. Meeting minds are brainstorming in person in NY, some are writing amazing letters, others are reaching out to influencial people with the greatest cause, full of ambition to achieve and to quote: "never surrender".
In the event that a higher offer comes in I include it is "one of many" possibilities that may or may not happen. To say that i talked to a "secretary" at Mario Gabelli Corp to "thank him for being a long" is assuming something that is just not true. In the event that they are long with OCAT, more power to them for a wise choice with all the many developments and patents the Lanza Team has developed to help the medical needs.
guy3, good thinking.
OCAT This morning after talking with Mario Gabelli Group, it came to me that in the event that OCAT goes on to $100.00 through all this situation, it will be because of Mario Gabelli in seeing true value in the OCAT Science along with shareholders.
They accepted the appreciation and said "no worries" will pass it on saying thankyou.
Lasers, you can say that again.
"Without a doubt. As well for certain Gabelli is NOT a penny flipper and will IMO hold long term for the big growth and/or $ profits from a higher Major Pharma bid."